WFA
ALLO icon

Wipfli Financial Advisors’s Allogene Therapeutics ALLO Stock Holding History

Wipfli Financial Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3K Buy
+243
New +$3.3K ﹤0.01% 2183

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wipfli Financial Advisors's ALLO Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Allogene Therapeutics (ALLO) in Q3 2022: 243 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2183 among its holdings.

192 funds tracked by Wall St. Rank hold ALLO as of Q3 2022.

  • Wipfli Financial Advisors held 243 shares of Allogene Therapeutics worth $3K as of Q3 2022.
  • Allogene Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Allogene Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2183 holding.
  • 192 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.